Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice

Experimental Neurology

Volumn 238, Issue 1, 2012, Pages 38-43

  Bard, Frédérique ^a   Fox, Michael ^b   Friedrich, Stuart ^c   Seubert, Peter ^a   Schenk, Dale ^a   Kinney, Gene G ^a   Yednock, Ted ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b ELAN PHARMACEUTICALS   (United States)

^c PFIZER INC   (United States)

Author keywords

3D6 clearance; Alzheimer's disease; Anti A antibody; Bapineuzumab; Blood brain barrier; Pharmacokinetics

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN ANTIBODY 3D6 I 125; BAPINEUZUMAB; IODINE 125; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY LABELING; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN REGION; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG TRANSPORT; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

AGING; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CEREBRAL CORTEX; HIPPOCAMPUS; HUMANS; KINETICS; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID;

EID: 84866538826     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.07.022     Document Type: Article

References (16)

1. Banks W.A., Terrell B., Farr S.A., Robinson S.M., Nonaka N., Morley J.E. Passage of amyloid b protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002, 23:2223-2226.
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
3. Bohrman B., Baumann K., Benz J., Gerber F., Huber W., Knoflach F., Messer J., Oroszlan K., Rauchenberger R., Richter W.F., Rothe C., Urban M., Bardroff M., Winter M., Nordstedt C., Loetscher H. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J. Alzheimers Dis. 2012, 28:49-69.
4. Broadwell R.D., Sofroniew M.V. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp. Neurol. 1993, 120:245-263.
5. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1550-1555.
6. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
7. Morgan D. Immunotherapy for Alzheimer's disease. J. Intern. Med. 2010, 269:54-63.
8. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
9. 11C-PIB PT assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
10. Röskam S., Neff F., Schwarting R., Bacher M., Dodel R. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. Neurosci. Biobehav. Rev. 2010, 34:487-499.
11. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mice. Nature 1999, 400:173-177.
12. Vieira P., Rajewski K. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 1988, 18:313-316.
13. Wang A., Das P., Switzer R.C., Golde T.E., Jankowsky J.L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-immunotherapy. J. Neurosci. 2011, 31:4124-4136.
14. Wilcock D.M., Rojiani A., Rosenthal A. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004, 24:6144-6151.
15. Wisniewski T., Boutajangout A. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct. Funct. 2010, 214:201-218.
16. Wurster U., Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J. Neurol. Neurosurg. Psychiatry 1994, 57:21-25. (Suppl.).